Linagliptin

Status
To Patients
Condition
COVID-19
Intervention Type
Oral Drug
Funder Type
Organization | University

Drug Details

Linagliptin is a dipeptidyl peptidase-4 inhibitor. It works by increasing the production of insulin and decreasing the production of glucagon by the pancreas.

Study Purpose

The purpose of this research is to see if the DPP4 inhibitor linagliptin, an oral medication commonly used to treat type 2 diabetes, can help with diabetes control and reduce the severity of the COVID-19 infection.

Find a Clinical Trial

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >